1. Nicotinamide suppresses hyperphosphatemia in hemodialysis patients
Yutaka Takahashi, Araki Tanaka, Tsukasa Nakamura, Tsutomu Fukuwatari, Katsumi Shibata, Noriaki Shimada, Isao Ebihara, Hikaru Koide 
Kidney International 
Volume 65, Issue 3, Pages (March 2004)
DOI: /j x
Copyright © 2004 International Society of Nephrology Terms and Conditions

2. Figure 1
Effect of nicotinamide on blood nicotinamide adenine dinucleotide (NAD) concentration in hemodialysis patients.-2weeks indicates the start of pretreatment washout. *vs. 0week, P < 0.01.
Kidney International  , DOI: ( /j x)
Copyright © 2004 International Society of Nephrology Terms and Conditions

3. Figure 2
Changes in serum phosphorus levels with nicotinamide treatment in hemodialysis patients.*vs. 0week, P < 0.001; **vs. 0week, P < 0.01.
Kidney International  , DOI: ( /j x)
Copyright © 2004 International Society of Nephrology Terms and Conditions

4. Figure 3
Serum calcium levels in relation to nicotinamide treatment in hemodialysis patients.
Kidney International  , DOI: ( /j x)
Copyright © 2004 International Society of Nephrology Terms and Conditions

5. Figure 4
Effect of nicotinamide treatment on calcium-phosphorus product in hemodialysis patients.*vs. 0week, P < ; ** vs. 0week, P < 0.01.
Kidney International  , DOI: ( /j x)
Copyright © 2004 International Society of Nephrology Terms and Conditions

6. Figure 5
Box and whisker plots showing serum intact parathyroid hormone (iPTH) levels in nicotinamide-treated hemodialysis patients.*vs. -2weeks, P < 0.05; **vs. 4weeks, P < 0.05.
Kidney International  , DOI: ( /j x)
Copyright © 2004 International Society of Nephrology Terms and Conditions